Even though clinical trials are pursuing the inhibition of ACLY to stall lipid accumulation in metabolic disorders, evidence supports that during fructose-induced fat accumulation ACSS2-processed acetate supplies substantial lipogenic acetyl-CoA independently of ACLY (Zhao et al, 2020). Here, ACLY is linked to metabolic disease.